Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin D for Letrozole-Induced Joint Pain
NCT00416715Phase 2
Key facts
- Status
- Completed
- Start
- Oct 2006
- Primary completion
- May 2010
- Countries
- 1
- Sponsor
- University of Washington
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Drugs
- vitamin d
- Conditions
- arthralgiamyalgiajoint stiffness
01
Overview
Phase 2, open-label trial of vitamin d in arthralgia, myalgia and joint stiffness, sponsored by University of Washington. Primary endpoint: Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness. Started Oct 2006; status: completed.
02
Design
- Study design
- Non-randomizedOpen-labelSingle group
03
Who it enrols
Postmenopausal women with Stage I-III breast cancer prescribed adjuvant letrozole who experience myalgias, arthralgias, or joint stiffness.
04
Endpoints
Primary
Number of Early Breast Cancer Patients Prescribed Adjuvant Letrozole That Are Vitamin D Deficient and Who Experience Myalgias, Arthralgias and/or Joint Stiffness
Beyond the preview
Go deeper on NCT00416715.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00416715.